Sangamo BioSciences Inc. (NASDAQ:SGMO) shares were up 2.2% during trading on Friday . The stock traded as high as $4.30 and last traded at $4.27, with a volume of 360,775 shares trading hands. The stock had previously closed at $4.18.

SGMO has been the subject of several analyst reports. Wells Fargo & Co. initiated coverage on Sangamo BioSciences in a report on Tuesday, May 3rd. They issued a “buy” rating for the company. Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Sangamo BioSciences in a report on Friday, May 6th. Jefferies Group restated a “buy” rating and issued a $14.00 target price on shares of Sangamo BioSciences in a report on Thursday, June 9th. Zacks Investment Research cut Sangamo BioSciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 5th. Finally, Janney Montgomery Scott cut Sangamo BioSciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $15.00 to $8.00 in a report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Sangamo BioSciences presently has a consensus rating of “Buy” and a consensus target price of $15.58.

The firm has a 50-day moving average price of $5.35 and a 200-day moving average price of $5.89. The firm’s market capitalization is $302.25 million.

Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.14. The company earned $3.70 million during the quarter, compared to analysts’ expectations of $5.38 million. During the same quarter in the previous year, the business posted ($0.17) EPS. Sangamo BioSciences’s quarterly revenue was down 56.0% on a year-over-year basis. On average, equities analysts predict that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current year.

A hedge fund recently raised its stake in Sangamo BioSciences stock. Schwab Charles Investment Management Inc. raised its position in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 25.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 254,000 shares of the biopharmaceutical company’s stock after buying an additional 52,171 shares during the period. Schwab Charles Investment Management Inc. owned about 0.36% of Sangamo BioSciences worth $2,320,000 at the end of the most recent reporting period.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.